A site where you can find recommended contractors for non-clinical testing|effical " Non-Clinical CROs and Agencies " Agno Pharmaceuticals

Agno Pharmaceuticals

Agno Pharmaceuticals is a CDMO that specializes in the development and manufacturing of complex dosage forms. Based in the United States, they function as a partner supporting the preclinical stage through GLP-compliant investigational drug product and API supply. This article introduces the characteristics of Agno Pharmaceuticals' non-clinical testing.

Features of Agno Pharmaceuticals' Non-clinical Testing Contract Services

Rapid manufacturing of GLP-compliant batches

Agno Pharmaceuticals isAble to rapidly manufacture API and intermediate batches that comply with GLP (Good Laboratory Practice) required for non-clinical studies.This is a significant strength. We optimize synthesis routes and develop processes from the early stages, carrying out manufacturing design with scale-up in mind. We can ensure quality and reproducibility not limited to supplying test samples, but with future clinical trials and commercial production transitions in view. Manufacturing and record-keeping comply with GLP requirements under our quality assurance system, providing high reliability for regulatory compliance and a solid foundation for smooth preclinical studies.

Development and supply of test articles for GLP toxicity studies

We support the development and supply of test articles used in GLP toxicity studies, playing a crucial role in the preclinical stage.Rather than simply providing the active pharmaceutical ingredient, we design and optimize it into a dosage form suitable for the actual route of administration and test conditions.We prepare materials for use in in vivo and in vitro testing. We can handle both sterile and non-sterile preparations, and utilize formulation technology to address challenges such as solubility and stability. We also support complex drug delivery technologies like nanoparticles and sustained-release formulations, and can flexibly handle projects involving poorly soluble or highly potent compounds. Supplies are produced and quality-controlled in accordance with GLP requirements, ensuring high regulatory compliance and providing a foundation for the accuracy and reproducibility of toxicity studies.

Integrated support from prototype design to scale-up

Consistent support from prototype formulation design to scale-up for preclinical testingWhat we can do is also one of our strengths. In the early stages, we design an appropriate dosage form based on the properties of the active ingredient, the route of administration, and the purpose of the study, and use formulation technology to address challenges such as solubility and stability. We then develop the formulated prototype not just as a test sample, but into a process design that considers clinical trials and future commercial production. This allows for risk reduction during scale-up and ensures reproducibility. By systematically verifying manufacturing conditions and quality characteristics, we achieve both development efficiency and consistent quality, supporting a smooth transition from preclinical to clinical development.

Handling highly difficult projects with advanced formulation technology and analytical infrastructure.

possessing diverse drug delivery technologies such as nanoparticulation, emulsification, gelation, hot-melt extrusion, and nanonillingWe can also handle difficult-to-handle substances such as poorly soluble compounds and highly potent active pharmaceutical ingredients (HPAPIs). We prepare candidate compounds that are difficult to evaluate with conventional methods for non-clinical testing through appropriate dosage form design. We also provide analytical services such as method development and validation, and stability testing (in compliance with ICH guidelines), ensuring both quality evaluation and data reliability. Our integrated technical platform allows for flexible responses to complex formulations and tests under special conditions.

An example of a disease model owned by Agno Pharmaceuticals

The pathological models I possess are not listed on the official website.

Agno Pharmaceuticals Non-clinical Trial Case Studies

Information on non-clinical study examples was not available on the official website.

Agno Pharmaceuticals Company Information

Address 3894 Courtney St, Bethlehem, PA 18017, USA
Tel +1-610-861-4701
Website https://agnopharma.com/
3 Recommended Contract Research Organizations for Non-Clinical Studies
— by Target goal and Expertise

In drug discovery, the quality and efficiency of non-clinical studies have a direct impact on clinical success rates, development costs, and overall length of time required in R&D. In recent years, there has been more demand for clinically relevant data, globally accepted reliability, and accurate early-stage screening. Thus, it is more important than ever to select the right CRO (Contract Research Organization) for strategic approach.
In this article, we highlight three CROs with proven technical capabilities, expertise, and long standing track records. These are our TOP 3 choices based on their capabilities and the specific target goals of the researchers for their non-clinical studies.

Pharmacology (Efficacy) Studies
Replicate unknown pathological models and
Discovery to clinically oriented drug evaluation
SMC Laboratories, Inc.
SMC Laboratories, Inc.
Reference: SMC Laboratories, Inc. official website (https://www.smccro-lab.com/jp/)
  • SMC Laboratories, Inc. has established a disease models using patented mouse technologies. The company has established proprietary pathological models—particularly in liver disease and fibrosis—and continues to expand their approach across a wide range of models in cancer, inflammation, and metabolic diseases.
  • From exploratory research to clinically oriented efficacy evaluation, SMC offers customized study designs, dosing strategies, and evaluation analysis tailored to each project. Their collaborative approachallows researchers to discuss and refine study plans together with SMC’s expert scientists.

  • With flexible small-scale study options and strong technical support, SMC Laboratories, Inc. is an ideal partner for start-ups, biotech ventures, and academic institutions alike.
Safety Studies
Comprehensive Safety Evaluation for FIH Applications
Labcorp Holdings Inc.
(Labcorp Drug Development)
Labcorp Holdings Inc.
Reference: Labcorp Holdings Inc. official website (https://jp.labcorp.com/)
  • Labcorp Holdings Inc. provides a fully integrated GLP testing system aligned with international regulatory standards, including FDA, EMA, and PMDA requirements. All studies are conducted under ICH-compliant quality assurance, making it ready for data submission.
  • The company has extensive expertise in long-term toxicity studies such as Segment I–III reproductive and carcinogenicity studies, as well as 2-year chronic toxicity assessments.
  • Labcorp Holdings Inc.’s comprehensive approach enables sponsors to efficiently outsource the entire preclinical package from toxicology, toxicokinetic (TK), and safety pharmacology study design to execution. This accelerates a path to First-in-Human (FIH) trials. For most of the global drug developers, this all-in-one service structure minimizes cost, risk, and expedite the time before advancing to clinical phase.
Pharmacokinetic (PK/PD) Studies
High-Precision Bioanalysis for Clinically Predictive PK/PD Evaluation
PhoenixBio Co., Ltd.
PhoenixBio Co., Ltd.
Source: PhoenixBio Co., Ltd. Official Website (https://phoenixbio.co.jp/)
  • PhoenixBio Co., Ltd.offers pharmacokinetic and hepatic metabolism studies using their proprietary PXB-mouse®, a humanized-liver chimeric mouse model. This platform enables the acquisition of data with high clinical correlation in ADME, drug–to-drug interaction studies, bridging the gap between preclinical and clinical stages.
  • With advanced LC-MS/MS-based bioanalysis, PhoenixBio Co., Ltd. provides aseamless workflow from plasma concentration measurement and metabolite identification to quantitative validation.

  • The company offersan integrated evaluation analysiscovering pharmacokinetics, hepatotoxicity, and safety with flexibility to accommodate complex modalities such as oligonucleotide and middle-molecule therapeutics. For compounds where hepatic metabolism is a development bottleneck—or where quantitative, reproducible exposure data are critical—PhoenixBio Co., Ltd. delivers unmatched analytical precision and consistency.

By region
list of animal models
Expertise & Track Record
3 Recommended Contract Non-Clinical Testing Services